Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Keefe, R. S.E. Search for Related Content PubMed Citation Articles by Keefe, R. S.E. Neuropsychology Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Cognition

Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol

OBJECTIVE: The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects of novel antipsychotic medications with those of high doses of conventional medications. This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis. METHOD: Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9.63 mg/day) or haloperidol (mean modal dose=4.60 mg/day) for the 12-week acute phase of a 2-year study. The patients were assessed with a battery of neurocognitive tests at baseline and 12 weeks after beginning treatment. RESULTS: An unweighted neurocognitive composite score, composed of measures of verbal fluency, motor functions, working memory, verbal memory, and vigilance, improved significantly with both haloperidol and olanzapine treatment (effect sizes of 0.20 and 0.36, respectively, no significant difference between groups). A weighted composite score developed from a principal-component analysis of the same measures improved to a significantly greater degree with olanzapine, compared with haloperidol. Anticholinergic use, extrapyramidal symptoms, and estimated IQ had little effect on the statistical differentiation of the medications, although duration of illness had a modest effect. The correlations of cognitive improvement with changes in clinical characteristics and with side effects of treatment were significant for patients who received haloperidol but not for patients who received olanzapine. CONCLUSIONS: Olanzapine has a beneficial effect on neurocognitive function in patients with a first episode of psychosis. However, in a comparison of the effects of olanzapine and low doses of haloperidol, the difference in benefit is small.

This article has been cited by other articles:

				P. M. Thompson, G. Bartzokis, K. M. Hayashi, A. D. Klunder, P. H. Lu, N. Edwards, M. S. Hong, M. Yu, J. A. Geaga, A. W. Toga, et al. Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments Cereb Cortex, October 8, 2008; (2008) bhn152v1. [Abstract] [Full Text] [PDF]

				T. R. E. Barnes, V. C. Leeson, S. H. Mutsatsa, H. C. Watt, S. B. Hutton, and E. M. Joyce Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia The British Journal of Psychiatry, September 1, 2008; 193(3): 203 - 209. [Abstract] [Full Text] [PDF]

				V. C. Leeson, T. R. E. Barnes, M. Harrison, E. Matheson, I. Harrison, S. H. Mutsatsa, M. A. Ron, and E. M. Joyce The Relationship Between IQ, Memory, Executive Function, and Processing Speed in Recent-Onset Psychosis: 1-Year Stability and Clinical Outcome Schizophr Bull, August 4, 2008; (2008) sbn100v1. [Abstract] [Full Text] [PDF]

				T. B. Halene and S. J. Siegel Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 230 - 239. [Abstract] [Full Text] [PDF]

				R. S. E. Keefe and P. D. Harvey Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks Schizophr Bull, July 1, 2008; 34(4): 656 - 663. [Abstract] [Full Text] [PDF]

				D. Dickinson and J. M. Gold Less Unique Variance Than Meets the Eye: Overlap Among Traditional Neuropsychological Dimensions in Schizophrenia Schizophr Bull, May 1, 2008; 34(3): 423 - 434. [Abstract] [Full Text] [PDF]

				V. Bubenikova-Valesova, A. Stuchlik, J. Svoboda, J. Bures, and K. Vales Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task PNAS, January 22, 2008; 105(3): 1061 - 1066. [Abstract] [Full Text] [PDF]

				R. S.E. KEEFE, J. A. SWEENEY, H. GU, R. M. HAMER, D. O. PERKINS, J. P. McEVOY, and J. A. LIEBERMAN Dr. Keefe and Colleagues Reply Am J Psychiatry, December 1, 2007; 164(12): 1911 - 1912. [Full Text] [PDF]

				T. E. Goldberg, R. S. Goldman, K. E. Burdick, A. K. Malhotra, T. Lencz, R. C. Patel, M. G. Woerner, N. R. Schooler, J. M. Kane, and D. G. Robinson Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect? Arch Gen Psychiatry, October 1, 2007; 64(10): 1115 - 1122. [Abstract] [Full Text] [PDF]

				R. S.E. Keefe, J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison Am J Psychiatry, July 1, 2007; 164(7): 1061 - 1071. [Abstract] [Full Text] [PDF]

				M. Morrens, W. Hulstijn, and B. Sabbe Psychomotor Slowing in Schizophrenia Schizophr Bull, July 1, 2007; 33(4): 1038 - 1053. [Abstract] [Full Text] [PDF]

				R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647. [Abstract] [Full Text] [PDF]

				T. A. Niendam, C. E. Bearden, J. Zinberg, J. K. Johnson, M. O'Brien, and T. D. Cannon The Course of Neurocognition and Social Functioning in Individuals at Ultra High Risk for Psychosis Schizophr Bull, May 1, 2007; 33(3): 772 - 781. [Abstract] [Full Text] [PDF]

				R. E. Gur, M. E. Calkins, R. C. Gur, W. P. Horan, K. H. Nuechterlein, L. J. Seidman, and W. S. Stone The Consortium on the Genetics of Schizophrenia: Neurocognitive Endophenotypes Schizophr Bull, January 1, 2007; 33(1): 49 - 68. [Abstract] [Full Text] [PDF]

				R. E. McCUE, R. WAHEED, L. URCUYO, G. ORENDAIN, M. D. JOSEPH, R. CHARLES, and S. M. HASAN Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia The British Journal of Psychiatry, November 1, 2006; 189(5): 433 - 440. [Abstract] [Full Text] [PDF]

				J. ADDINGTON, H. SAEEDI, and D. ADDINGTON Influence of social perception and social knowledge on cognitive and social functioning in early psychosis The British Journal of Psychiatry, October 1, 2006; 189(4): 373 - 378. [Abstract] [Full Text] [PDF]

				S. J. Wood, G. E. Berger, M. Lambert, P. Conus, D. Velakoulis, G. W. Stuart, P. Desmond, P. D. McGorry, and C. Pantelis Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry, September 1, 2006; 63(9): 969 - 976. [Abstract] [Full Text] [PDF]

				A. E. Thornton, J. X. Van Snellenberg, A. A. Sepehry, and W. G. Honer The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review J Psychopharmacol, May 1, 2006; 20(3): 335 - 346. [Abstract] [PDF]

				J. R Bola Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm? Schizophr Bull, April 1, 2006; 32(2): 288 - 296. [Abstract] [Full Text] [PDF]

				D. Koren, L. J Seidman, M. Goldsmith, and P. D Harvey Real-World Cognitive--and Metacognitive--Dysfunction in Schizophrenia: A New Approach for Measuring (and Remediating) More "Right Stuff" Schizophr Bull, April 1, 2006; 32(2): 310 - 326. [Abstract] [Full Text] [PDF]

				P. D. Harvey, J. Rabinowitz, M. Eerdekens, and M. Davidson Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial Am J Psychiatry, October 1, 2005; 162(10): 1888 - 1895. [Abstract] [Full Text] [PDF]

				D. M. Gardner, R. J. Baldessarini, and P. Waraich Modern antipsychotic drugs: a critical overview Can. Med. Assoc. J., June 21, 2005; 172(13): 1703 - 1711. [Abstract] [Full Text] [PDF]

				J. A. Lieberman, G. D. Tollefson, C. Charles, R. Zipursky, T. Sharma, R. S. Kahn, R. S. E. Keefe, A. I. Green, R. E. Gur, J. McEvoy, et al. Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis Arch Gen Psychiatry, April 1, 2005; 62(4): 361 - 370. [Abstract] [Full Text] [PDF]

				R. W Buchanan, M. Davis, D. Goff, M. F Green, R. S E Keefe, A. C Leon, K. H Nuechterlein, T. Laughren, R. Levin, E. Stover, et al. A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia Schizophr Bull, January 1, 2005; 31(1): 5 - 19. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us